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AbstrAct
Bovine herpesvirus type 1 (BoHV-1) is the causative agent 
for infectious bovine rhinotracheitis and infectious pustular 
vulvovaginitis in cows or balanoposthitis in bulls. In this 
study, individual and bulk tank milk (BTM) samples from 
5 Catalan dairy farms with different control strategies 
against BoHV-1 were analysed during the course of a 
year for milk quality parameters and glycoprotein E (gE) 
antibodies. Detection of gE antibodies was carried out with 
ELISA techniques. Prevalence of BoHV-1 varied between 
farms, and was stable during the study in individual and 
BTM samples. Comparing the antibody results of samples 
with milk quality parameters, positive samples with higher 
levels of antibodies corresponded to lower lactose and to 
higher percentages of fat and somatic cells.
IntroductIon
Bovine herpesvirus type 1 (BoHV-1) is an 
important pathogen of cattle, mainly in the 
respiratory and genital tracts, causing infec-
tious bovine rhinotracheitis (IBR), infectious 
pustular vulvovaginitis (IPV) and infectious 
pustular balanoposthitis, but also causing 
abortion and infertility. The virus can also 
cause fatal multisystemic infection and 
encephalomyelitis before birth or early post-
natal BoHV-1 infection in neonatal calves 
(Muylkens and others 2007), conjunctivitis, 
mastitis, enteritis and dermatitis (Wyler and 
others 1989, Straub 2001).
BoHV-1 and other viral infections can play 
a direct or indirect role in the aetiology of 
bovine mastitis (Wellenberg and others 2002, 
Barkema and others 2009), thereby affecting 
milk quality parameters (Halasa and others 
2007). It has been observed that milk param-
eters of quarters with subclinical mastitis 
compared with healthy ones had a signifi-
cantly higher somatic cell count (SCC) but a 
lower fat content (Tomazi and others 2015).
BoHV-1 can remain latent during the life-
time of the host in the trigeminal ganglion or 
pharyngeal tonsils following a primary infec-
tion of the conjunctiva, oral and/or nasal 
cavities, or in the sacral ganglia following geni-
talia infection (Ackermann and Wyler 1984, 
Winkler and others 2000) or can be reacti-
vated by factors that cause stress or alter the 
immune status of the animal such as parturi-
tion (Thiry and others 1985), transportation 
(Thiry and others 1987), mixing of animals, 
animal movements (Jones and Chowdhury 
2010), inclement weather (Van DRUNNEN 
LITTEL-van den HURK 2006), concomitant 
infection, poor husbandry or diet (Turin and 
others 1999), overcrowding (Van DRUNNEN 
LITTEL-van den HURK 2006) or following 
treatment with corticosteroids (Winkler and 
others 2000).
BoHV-1 is a widely disseminated pathogen 
displaying significant differences in regional 
incidence and prevalence with regard to 
geographical location and breeding manage-
ment in the regions under consideration 
(Van Schaik and others 1998, Ackermann 
and Engels 2006). IBR/IPV disease is listed by 
the World Organisation for Animal Health.
The requirement for ‘IBR-free’ status in 
EU countries restricts the importation of 
cattle from endemically infected regions. 
These rules have motivated several European 
countries or regions to establish control and/
or eradication programmes (Raaperi and 
others 2014). According to EU directives, 
Catalonia is under an official IBR eradica-
tion programme that combines the use of 
a strategy for differentiating infected from 
vaccinated animals and culling seropositive 
animals. Since January 2013, the purchase of 
BoHV-1-positive animals has been prohibited 
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and vaccination of dairy cows is only allowed when a 
marker (glycoprotein E (gE) deleted) vaccine is used. 
Elimination of positive animals and the use of any vaccine 
will be prohibited in 2020 ( gencat. cat).
The most common method for the control of IBR 
infection in Catalan herds has been vaccination of both 
seropositive and seronegative animals in order to mini-
mise or exclude the possibility of activation of latent IBR 
infection in the herd by reducing the amount of virus 
excreted following reactivation (Bosch and others 1997, 
Mars and others 2001).
The main objective of this study was to examine the 
relationship between antibody levels in the milk of indi-
vidual cows and milk quality parameters over the course 
of a year. At the same time, the authors wanted to deter-
mine the percentage of positive cows by measuring 
BoHV-1 antibodies present in the bulk tank milk (BTM) 
and in each lactating cow of the five farms over the four 
samplings. A further aim was to determine whether tank 
analysis was sufficient to ascertain and predict the health 
of a farm in terms of BoHV-1 without carrying out indi-




The study was conducted on five high production 
commercial closed dairy farms in Lleida, Catalonia 
(north-east Spain) during the course of a year from 
September 2013 to August 2014. Farms 1 to 5 had 
an average of 65, 335, 123, 205 and 441 lactating 
Holstein-Friesian cows, respectively. The average 
production of the farms was 9500–11100 kg of milk 
(3.6% fat and 3.3% protein) in 305 days per cow. 
Average number of lactation ranged between 2.4 and 
2.6. Cows in lactation were housed either in cubicles or 
free-stall barn straw bedded and they were fed a total 
mixed ration consisting of corn silage, grass silage 
and concentrates. Cows were milked two (at 6:00 and 
18:00) or three times a day (at 4:00, 12:00 and 20:00).
Calving was either individually or in small groups of dams 
(maximum 5). Cows were housed in free-stall straw bedded 
pen, and calves were separated from the mother within 
three hours of birth in all farms and received colostrum.
Breeding management was carried out by artificial 
insemination (AI) with Holstein-Friesian (IBR-free) 
commercial semen performed by highly trained techni-
cians or veterinarians specialised in reproduction.
On four farms (farms 2, 3, 4 and 5), each cow was 
sampled and analysed for milk, fat, protein, lactose, dry 
matter extract, and urea concentration and SCC by the 
Catalan Interprofessional Dairy Association Laboratory 
(ALLIC, Associació Interprofessional Lletera de Catalunya, 
Cabrils, Barcelona) once a month. Farm 1 was not under 
individual sampling. On all five farms BTM was analysed 
daily for milk quality.
Farms were chosen in order to study different IBR 
statuses and controls, taking account of management, 
vaccination and biosecurity.
The use of vaccines on the farms was variable and 
included: double deleted (gE− and thymidine-kinase 
enzyme (tK)) IBR vaccine (HIPRAbovis IBR Marker live, 
HIPRA, Girona, Spain) and trivalent vaccine (HIPRA-
bovis Balance, HIPRA, Girona, Spain) for bovine viral 
diarrhoea virus, bovine respiratory syncytial viru and 
parainfluenza virus type 3. The vaccination programme 
varied: farm 1 never used vaccines; farms 2 and 5 stopped 
vaccinating animals against the above mentioned 
diseases in May 2011 and December 2012, respectively. 
Farm 2 restarted vaccination in May 2013. Farms 3 and 
4 followed a standard blanket vaccination protocol of all 
animals over eight months of age on the holding every six 
months. No animals were purchased during the last 10 
years in any farm except farm 5 which bought 60 IBR-free 
heifers in 2010.
samples
For this study, BTM samples and individual milk samples 
were collected over four consecutive seasons (autumn 
and winter of 2013, spring and summer of 2014; 
named as 1, 2, 3 and 4, respectively). Individual (from 
four farms) and BTM samples were obtained from the 
routine collections of the ALLIC programme on these 
farms. This laboratory analysed individual milk samples 
and BTM samples for fat, protein, lactose, dry matter 
extract and urea concentration, SCC and bacteriology. 
Individual milk samples and BTM samples analysis for 
fat, protein and lactose concentrations was carried out 
by Fourier transform infrared spectroscopy (FTIR) on 
a Foss MilkoScan FT+ (Foss A/S, Hillerod, Denmark), 
SCC was determined using a Foss Fossomatic FC (Foss 
A/S, Hillerod, Denmark) and bacteriology was deter-
mined using a Foss BactoScan FC+ (Foss A/S, Hillerod, 
Denmark). Once samples had been routinely analysed 
for milk quality, they were sent in 50 ml containers and 
refrigerated (+4°C) to the Animal Science Department 
Laboratory (Universitat de Lleida) where they were 
processed and analysed using an ELISA technique. On 
farm 1, which did not follow the ALLIC individual milk 
sampling protocol, investigators conducted individual 
milk sampling over all four seasons during the study.
BTM samples contained azidiol (bacteriostatic preserva-
tive) and individual milk samples bronopol (bactericidal 
preservative) to preserve the milk longer. Addition of 
preservatives in milk and storage time does not influence 
the results of antibody detection (Wellenberg and others 
1998).
elIsA technique
The BoHV-1 antibody levels were determined using a 
commercial gE-blocking ELISA test kit (CIVTEST BOVIS 
IBRgE; HIPRA, Girona, Spain) with a sensitivity of 89.5% 
(95% confidence interval (CI) 84.73% to 92.90%) and 
specificity of 96.84% (95% CI 95.34% to 97.87%) in sera 
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(Rebordosa-Trigueros and others 2012). The kit detects 
antibodies to a specific gE BoHV-1 and is able to distin-
guish vaccinated from naturally infected animals. The 
manufacturer's instructions were strictly followed, using 
the kit reagents and controls provided.
Before the development of the technique, samples were 
prepared and left in the refrigerator (+4°C) for 20 hours 
to separate the cream fraction on the top from skimmed 
milk below. Once the two phases were separated, the 
top milk cream band was discarded and the skimmed 
milk obtained. Skimmed milk samples were dispensed 
into microtubes arranged in special racks with the same 
layout as the ELISA plates (96 microtubes arranged in 
12 columns and 8 rows) and numbered by relating them 
to the identification number of each cow. These samples 
were frozen (−20°C) until analysis.
The first BTM samples were also processed as concen-
trated (n=9), in order to increase sensitivity of the test 
without affecting specificity and thus validate the result 
of non-concentrated samples. The IgGs concentration 
procedure was carried out in strict accordance with the 
manufacturer's instructions, using the kit reagents and 
controls provided. (HIPRA-CIVTEST BOVIS IBRgE 
MILK [Ab] leaflet, 709031–00 version)
Before analysis, samples were thawed at room tempera-
ture. Samples were placed in the ELISA microplate wells 
according to the protocol. All tests were performed 
according to the manufacturer’s instructions. The absor-
bance was measured as optical density (OD) values at 
450 nm using a microplate reader (Multiskan FC Thermo 
Fisher Scientific). The results were expressed as inhibi-
tion percentages (%IN) calculated as follows
 
%IN =
Average OD450 Negative Control−OD450 Sample
Average OD450 Negative Control
x100 
According to manufacturer's instructions (Table 1) 
samples of non-concentrated BTM and individual milk 
were considered negative if the %IN value was up to 25 and 
positive if the value was more than 25 (in BTM samples 
this cut-off value corresponds to prevalence ≥25%). 
Samples of concentrated BTM were considered negative 
if the %IN value was less than 5 and positive if the value 
was at least 5 (which corresponds to prevalence ≥4%). 
Combination of %IN values in BTM samples considered 
positive when concentrated (%IN≥5) and negative when 
non-concentrated (%IN≤25) was useful to determine 
some estimated ‘low-positive’ prevalence (4%–25%).
data analysis
Prevalence of animals positive to BoHV-1 was calculated 
every time that individual milk sample collection was 
performed. This analysis was conducted using the frequency 
(FREQ) procedure of SAS V.9.2 (Statistical Analysis Soft-
ware, Cary, North Carolina, USA). Lower and higher 
confidence limits for the proportion of positive animals was 
calculated at 95%. For individual milk samples, a repeated 
measurements analysis of variance (PROC MIXED of SAS) 
was performed to determine whether the quality parame-
ters of milk, such as protein, lactose, fat, dry matter extract, 
urea and somatic cells varied between positive and negative 
animals. The statistical model included cow as a random 
effect (to account for repeated data) and the fixed effects 
of farm, date of collection and status of BoHV-1 positivity. 
Data imbalance between farms was taken into account, as 
some contributed with many positive animals and others 
with few positives, and least square means and standard 
errors were calculated.
results
During the study, individual milk (n=4250), concentrated 
BTM (n=9) and non-concentrated BTM (n=20) samples 
were analysed. The total positive individual samples against 
BoHV-1 on all farms during the study period were 1403 
(33%) and 2847 (67%) samples were negative. As regards 
concentrated BTM samples, one sample was negative 
(prevalence <4%) and eight samples were positive (preva-
lence ≥4%). When BTM samples were not concentrated, 5 
were positive (prevalence ≥25%) and 15 negative (<25%). 
Six samples were negative when non-concentrated and 
became positive when concentrated, where interpretation 
is: prevalence 4%–25% (Table 2).
relation between individual milk and btM samples
Farm 1 was always BoHV-1-negative in all individual or 
bulk tank analyses. The four remaining farms (2–5) 
always had BoHV-1-positive cows: farm 2 always showed 
a very high positivity for both individual (>92% of posi-
tive animals) and BTM, whether concentrated or not 
(%IN >81%). Farms 3, 4 and 5 maintained a proportion 
of positive animals below 10.0%, except for sampling 
1 on farm 5, with a prevalence of 10.1% although this 
decreased in subsequent samplings (Table 2).
In the present study, BTM samples were positive 
when individual prevalence was very high (>92%) 
as observed on farm 2. Non-concentrated BTM 
samples were negative (cut-off ≤25) when individual 
TAble 1: Relation between inhibition percentage (IN%) 
values of the ELISA, prevalence value of the bulk tank milk 
(BTM) sample and positivity to bovine herpesvirus type 
1 (BoHV-1) of individual samples. Source: HIPRA-Civtest 
bovis IBRgE MILK [Ab] leaflet, 709031–00 version




  Higher than 25.0 Prevalence ≥25% Positive sample




  Higher than or equal 
to 5.0
Prevalence ≥4% Positive sample
  Lower than 5.0 Prevalence <4% Negative sample
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prevalence was below 11.00%. Concentration of BTM 
samples was useful to determine some estimated 
‘low-positive’ prevalence (4%–25%) that resulted as 
negative in non-concentrated BTM samples. Farms 
3, 4 and 5 always showed low individual prevalence 
data (<10.11%) and a good correlation between indi-
vidual and bulk tank results, whether concentrated 
or not.
trends in individual results over the course of a year
As cows were analysed several times, depending on 
the lactation period of each one, in order to validate 
consistency of the results of the different sampling 
periods, the cows were classified as follows: positive 
(all samples were positive) (n=468), negative (all 
samples were negative) (n=1021), converted to posi-
tive (negative samples followed always by positive 
samples) (n=23) and inconsistencies (positive animals 
becoming negative, or after a first positive assessment 
alternating between negative and positive results) 
(n=46).
comparison with milk quality parameters
A total of 4150 individual milk samples from farms 2, 
3, 4 and 5 were analysed for milk quality parameters. 
Only consistent cows, always positive or always negative, 
were used to find the relationship between positivity to 
BoHV-1 and a change in any of the milk quality parame-
ters (Table 3).
Fat, logarithm of somatic cells and lactose differed signifi-
cantly (P=0.045, P<0.0001 and P<0.0001, respectively) 
between BoHV-1-positive and BoHV-1-negative samples. 
Milk from animals positive for BoHV-1 had a higher 
percentage of fat (3.90%), a higher SCC (2.26×1000/
ml) and lower lactose (4.68%) compared with milk from 
animals negative for BoHV-1 (3.71%, 1.99×1000/ml and 
4.82%). Linear regression detected no linear relation-
ship between the level of BoHV-1 antibodies and any 
of the milk quality variables. The statistically significant 
higher levels of SCC and fat, and lower levels of lactose, 
for positive cows in the overall data set was consistent 
within farms.







Farm Sampling* % positive animals† (LCL–HCL 95%) %IN‡ BTM
(cut-off≤25)
%IN BTM concentrated (cut-
off≤5)
Calculated prevalence
1 1 0.0 0.0 (neg) 0.0 (neg) <4%
2 0.0 0.0 – –
3 0.0 0.0 – –
4 0.0 0.0 – –
2 1 97.6 (96.1–99.2) 92.5 (pos) 96.0 (pos) ≥25%
2 93.9 (91.3–96.4) 89.7 (pos) 93.5 (pos) ≥25%
3 98.2 (96,7–99.6) 81.9 – –
4 92.12 (89.2–95.0) 89.3 – –
3 1 4.5 (0.6–8.4) 6.4 (neg) 35.5 (pos) 4%–25%
2 1.7 (0.00–4.0) 10.6 (neg) 12.1 (pos) 4%–25%
3 1.5 (0.0–3.5) 0.00 – –
4 0.8 (0.0–2.4) 0.9 – –
4 1 5.0 (1.8–8.2) 11.2 (neg) 40.5 (pos) 4%–25%
2 4.00 (1.1–6.9) 18.1 (neg) 30.3 (pos) 4%–25%
3 2.2 (0.1–4.3) 0.00 – –
4 2.8 (0,4–5.3) 19.5 – –
5 1 10.1 (6.9–13.2) 20.8 (neg) 48.6 (pos) 4%–25%
2 6.5 (4.0–9.0) 19.9 (neg) 37.6 (pos) 4%–25%
3 5.3 (3.1–7.5) 0.00 – –
4 6.3 (3.8–8.8) 19.5 – –
*Number of sampling. 1=autumn, 2= winter, 3= spring and 4= summer.
†% Positive animals referred for individual analysis.
‡%IN: inhibition percentages.
Estimated prevalence according to the results of the BTM, whether concentrated or not.
BoHV-1, bovine herpesvirus type 1; BTM, bulk tank milk; HCL, higher concentration limit; LCL, lower concentration limit.
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dIscussIon
relationship between individual and bulk tank results
Using milk tank samples is of great interest due to the 
ease of processing and low cost (Nylin and others 1999). 
Nevertheless, the results of these samples should be inter-
preted only as indicative due to the low sensitivity that 
blocking IBR gE-ELISAs have on tank samples (Kramps 
and others 2004). BTM samples should be accompa-
nied regularly by an individual test and concentrated 
tank samples in order to increase the sensitivity of the 
ELISA technique without affecting specificity (Schro-
eder and others 2012, Rebordosa-Trigueros and others 
2012). Unfortunately, concentration of milk samples is 
not automated yet and requires specialised personnel 
and time. For this reason, the study only used the tech-
nique of concentration for the first two sampling seasons 
to compare with the non-concentrated BTM technique 
which is less expensive at the laboratory level. Low sensi-
tivity of the IBR gE-ELISA in non-concentrated BTM 
samples can be a major problem in IBR control or 
eradication programmes, above all on farms with low 
individual prevalence (Raaperi and others 2010, Rola 
and others 2015).
In this study, a prevalence below 11% proved negative 
in non-concentrated BTM testing and positive in concen-
trated BTM testing. An individual prevalence higher than 
80% proved positive (estimated prevalence ≥25%) in BTM 
testing, whether concentrated or not. Similar results have 
also been observed in other studies (Wellenberg and others 
2002) where in individual testing (milk or serum) less than 
10% was considered ‘BTM negative’ and when individual 
prevalence was more than 50%, this was considered ‘BTM 
positive’ (Hartman and others 1997, Raaperi and others 
2010, Porquet garanto 2012). Unfortunately, the farms 
under study had both a very high or very low individual 
prevalence, and the relationship between individual perfor-
mance and milk tank farms with an average prevalence of 
disease could not be studied.
When BTM sampling, the recommendation for 
repeated testing in order to increase sensitivity is justi-
fied (Eliot and Franken (1997)). Importantly, a total 
correlation between individual and bulk tank results in 
the case of a totally ‘IBR-free’ farm (farm 1) was main-
tained.
Individual results
The total number of individual milk samples varied during 
the study because lactating cows were not always the same 
with regard to the dynamics of the dairy production system 
(dry-off period, first parturition and culled cows). In order 
to avoid false-negative animals, repeated testing was carried 
out wherever possible on all farms included in the study 
(Raaperi and others 2014).
Conversion of animals to positive was low on all the 
farms studied (average 1.6%; from 0.0% to 2.7%), this 
could be due to the use of a ‘double deleted’ vaccine on 
all the farms (except in farm number 1), reducing the risk 
of spread and vaccine virus recombination (Raaperi and 
others 2014). Inconsistent results were also low (average 
3.4%; from 0.0% to 5.3%), these cases can be attributed 
to false-positives, especially on farms with low prevalence 
(Geraghty and others 2012).
comparison with milk quality parameters
Although many infectious and non-infectious factors 
can affect individual SCC and milk quality of cows, this 
study suggests that BoHV-1 infection may influence these 
parameters. The role that BoHV can play in the immu-
nosuppression status of animals could explain these 
results. Individual fat and SCCs were significantly higher 
in BoHV-1-positive samples (3.90% and 2.19×1000/ml) 
compared with BoHV-1-negative samples (3.69% and 
1.99×1000 ml). On the other hand, individual lactose was 
significantly lower in BoHV-1-positive samples (4.68%) 
compared with negative samples (4.82%). A Polish study 
found similar results evaluating BoHV-1 status and milk 
quality parameters in BTM during the course of a whole 
year, observing that farms with a higher BoHV-1 infec-
tion status had significantly higher BTM SCCs and fat 
content, but differences in protein and total bacteria 
were not observed (Rola and others 2015). Milk quality 
parameters and milk production were studied during a 
subclinical infection of BoHV-1 on a Dutch dairy farm, 
where no influence of the infection on SCC and fat were 
observed, although a significant drop in milk production 
in initially seronegative cows was reported (Hage and 
others 1998). Another study found a statistical difference 
in the mean SCC between cows positive for BoHV but 
without concurrent bacterial infection and cows without 
BoHV and bacterial intramammary infection (IMI). In 
this study, the authors concluded that the major influ-
ence on milk SCC was bacterial IMI rather than viral 
influence (Herlekar and others 2013). To the authors’ 
knowledge, no studies have reported differences in 
lactose percentage in individual milk samples consid-
ering positivity to BoHV-1 infection.
TAble 3: Regression results (GLM) between the milk 
quality parameters of 3874 samples compared with BoHV-1-
positive and BoHV-1-negative antibodies status. Values are 
means±se (n=1331 samples from 462 cows always positive 







Fat * 3.90±0.073 3.71±0.030 0.045
Protein* 3.39±0.025 3.32±0.014 0.2
Lactose* 4.68±0.025 4.82±0.010 <0.0001
ESM* 8.81±0.045 8.87±0.019 0.3
Log(som cells)† 2.26±0.059 1.95±0.025 <0.0001
Urea‡ 98.18±3.86 90.37±1.58 0.1
*%.
†Somatic cell count (x1000/ml).
‡ mg/L.
ESM, dry non-fat-milk-material content; GLM, generalized linear 
model.
group.bmj.com on January 25, 2018 - Published by http://vetrecordopen.bmj.com/Downloaded from 
Open Access
6 Armengol R, et al. Vet Rec Open 2017;4:e000203. doi:10.1136/vetreco-2016-000203
The higher SCC and fat values of BoHV-1-positive samples 
detected within all the farms supports the results obtained 
overall, although unfortunately, the reduction in sample 
size when comparing within farms fails to confirm statis-
tically the effect on all the farms. More studies should be 
conducted in the future in order to increase the sample size 
within the farm and the number of farms to compare and 
to confirm whether BoHV-1 affects the milk quality param-
eters in closed and quite stable farms, under control and 
vaccination programs for BoHV-1 and without any recent or 
ongoing outbreaks caused by BoHV-1.
conclusIons
The results of the present study showed that repeated 
BTM ELISA tests for BoHV-1 appear to be a very useful 
tool to evaluate the development of seropositivity for 
BoHV-1 within a herd. BoHV-1 infection can affect milk 
quality parameters, increasing SCC and fat in individuals.
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